CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 73 enrolled
Drug / intervention
18F-GP1 PET CTother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03943966
NCT03943966N/ACompleted

In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer

University of Edinburgh·interventional·Posted May 9, 2019·Updated Oct 14, 2021

In Brief

A clinical study evaluating 18F-GP1 PET CT for Thrombosis and 10 related conditions. Completed, enrolled 73 participants across 1 site.

Detailed Summary

To date, the investigators have successfully employed a radiotracer (18F-sodium fluoride) as a marker of necrotic inflammation in human atherosclerosis. The investigators aim to further the mechanistic understanding of atherothrombosis by studying the activation of glycoprotein IIb/IIIa receptors in cardiovascular thrombus using the novel platelet radiotracer (18F-GP1). Binding of 18F-GP1 to activated platelets in venous and arterial thrombi has already been demonstrated in pre-clinical studies and a phase 1 trial in man. If successful, this study would define the role of the glycoprotein IIb/IIIa receptor within in vivo thrombosis across a range of cardiovascular diseases.

Study Details

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 9, 2019
Enrollment StartNov 11, 2019
Primary CompletionJul 2, 2021
Study CompletionOct 13, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.1 years ago

Interventions

18F-GP1 PET CTother

PET CT scan using platelet radiotracer 18F-GP1